Conference Coverage

Device-related thrombus associated with ischemic events

 

Key clinical point: Device-related thrombus (DRT) following left atrial appendage closure occurs in less than 4% of patients but is associated with a higher rate of stroke and systemic embolism vs. no DRT.

Major finding: The rate of ischemic stroke and systemic embolism was 6.28 and 1.65 per 100 patient years for patients with DRT and with no DRT, respectively (P less than .001).

Study details: Analysis of data from the device arms of four prospective clinical trials.

Disclosures: The Watchman studies were funded by Boston Scientific, the company that markets the device. Dr. Reddy has been a consultant to and has received research funding from Boston Scientific and from Abbott and Biosense-Webster, and he reported having an equity interest in Javelin and Surecor. Coauthors reported disclosures related to Boston Scientific, Johnson & Johnson, Abbott, and other medical device companies. Dr. De Lurgio has been a consultant to Boston Scientific.

Source: Dukkipati SR et al. Circulation. 2018 May 11. doi: 10.1161/CIRCULATIONAHA.118.035090.


 

REPORTING FROM HEART RHYTHM 2018

Updated, 5/17/18: This article has been updated with reporting from Mitchel L. Zoler at the meeting, and has been revised for clarity and to reflect that the results were presented by Dr. Reddy.

SOURCE: Dukkipati SR et al. Circulation. 2018 May 11. doi: 10.1161/CIRCULATIONAHA.118.035090.

Next Article:

   Comments ()